180 Life Sciences Corp.
ATNF
$2.00
$0.010.50%
| Weiss Ratings | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Fair | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Fair | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Very Weak | |||
| Beta / Standard Deviation | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | 0.35 | |||
| Price History | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -4.19% | |||
| 30-Day Total Return | -48.88% | |||
| 60-Day Total Return | -54.99% | |||
| 90-Day Total Return | -48.77% | |||
| Year to Date Total Return | -53.18% | |||
| 1-Year Total Return | -91.00% | |||
| 2-Year Total Return | -99.67% | |||
| 3-Year Total Return | -99.95% | |||
| 5-Year Total Return | -99.95% | |||
| 52-Week High % Change | -93.67% | |||
| 52-Week Low % Change | 32.99% | |||
| Price | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $27.93 | |||
| 52-Week Low Price | $1.33 | |||
| 52-Week Low Price (Date) | Apr 16, 2024 | |||
| 52-Week High Price (Date) | May 19, 2023 | |||
| Valuation | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 1.55M | |||
| Enterprise Value | 630.39K | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -64.01 | |||
| Earnings Per Share Growth | -81.36% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -7.62 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $1.83 | |||
| Enterprise Value/EBITDA (TTM) | -0.04 | |||
| Enterprise Value/EBIT | -0.04 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 622.90K | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 650 507 0669 | |||
| Address | Building 4 Palo Alto, CA 94306 | |||
| Website | 180lifesciences.com | |||
| Country | United States | |||
| Year Founded | -- | |||
| Profitability | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -67.63% | |||
| Return on Equity | -- | |||
| Income Statement | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -13.37M | |||
| EBIT (TTM) | -13.48M | |||
| Net Income (TTM) | -19.94M | |||
| Net Income Avl. to Common (TTM) | -19.94M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | 94.36% | |||
| EPS Diluted (TTM) | -64.01 | |||
| EPS Diluted Growth (Q YOY) | 98.94% | |||
| Balance Sheet | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 1.98M | |||
| Cash Per Share (Q) | $3.17 | |||
| Total Current Assets (Q) | 3.64M | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -127.70K | |||
| Current Ratio (Q) | 0.719 | |||
| Book Value Per Share (Q) | -$0.24 | |||
| Total Assets (Q) | 5.26M | |||
| Total Current Liabilities (Q) | 5.06M | |||
| Total Debt (Q) | 1.05M | |||
| Total Liabilities (Q) | 5.39M | |||
| Total Common Equity (Q) | -127.70K | |||
| Cash Flow | ATNF - NASDAQ | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 5.91M | |||
| Net Change in Cash (TTM) | -4.99M | |||
| Levered Free Cash Flow (TTM) | -6.09M | |||
| Cash from Operations (TTM) | -10.92M | |||
